Hematologic Malignancy
Plasma Cell Neoplasm
CI-CAN-00006438Explore in graph →
HematologicNon-malignant831 active trials25 approved drugs26 evidence items
Loading cancer entity…
Hematologic Malignancy
CI-CAN-00006438Explore in graph →
Clinical trials
3,421 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT05527340 | Iberdomide-dexamethasone Alone or in Combination With Standard MM Treatment Regimens in Transplant Ineligible Newly Diagnosed Patients. | active not recruiting | Phase 2 | 140 | PETHEMA FoundationOTHER | 1 | May 8, 2026 | clinicaltrials |
| NCT07377435 | DC/MM Fusion Vaccine With BCMA CAR-T in R/R MM | recruiting | Phase 1 | 25 | David AviganOTHER | 1 | May 8, 2026 | clinicaltrials |
| Clinical Study of TQB2934 Injection in Relapsed/Refractory Multiple Myeloma |
| not yet recruiting |
| Phase 3 |
| 260 |
| Chia Tai Tianqing Pharmaceutical Group Co., Ltd.INDUSTRY |
| 1 |
| May 8, 2026 |
| clinicaltrials |
| NCT02269592 | Study of MGUS, Smoldering Myeloma, Early MDS and CLL to Assess Molecular Events of Progression and Clinical Outcome | recruiting | — | 10,000 | Dana-Farber Cancer InstituteOTHER | 1 | May 7, 2026 | clinicaltrials |
| NCT04439266 | Testing Crizotinib as a Potential Targeted Treatment in Cancers With ALK Genetic Changes (MATCH-Subprotocol F) | active not recruiting | Phase 2 | 5 | National Cancer Institute (NCI)NIH | 1 | May 7, 2026 | clinicaltrials |
| NCT04439279 | Testing Trametinib as a Potential Targeted Treatment in Cancers With BRAF Genetic Changes (MATCH-Subprotocol R) | active not recruiting | Phase 2 | 35 | National Cancer Institute (NCI)NIH | 1 | May 7, 2026 | clinicaltrials |
| NCT04439331 | Testing VS-6063 (Defactinib) as a Potential Targeted Treatment in Cancers With NF2 Genetic Changes (MATCH-Subprotocol U) | active not recruiting | Phase 2 | 35 | National Cancer Institute (NCI)NIH | 1 | May 7, 2026 | clinicaltrials |
| NCT04439344 | Testing Binimetinib as a Potential Targeted Treatment in Cancers With NRAS Genetic Changes (MATCH-Subprotocol Z1A) | active not recruiting | Phase 2 | 53 | National Cancer Institute (NCI)NIH | 1 | May 7, 2026 | clinicaltrials |
| NCT06799026 | A Phase 1 Study of Vaccination With Dendritic Cell (DC)/Multiple Myeloma (MM) Fusions in Combination With Elranatamab in Relapsed or Refractory Multiple Myeloma | recruiting | Phase 1 | 25 | David AviganOTHER | 1 | May 7, 2026 | clinicaltrials |
| NCT04126200 | Platform Study of Belantamab Mafodotin as Monotherapy and in Combination With Anti-cancer Treatments in Participants With Relapsed/Refractory Multiple Myeloma (RRMM)(DREAMM 5) | active not recruiting | Phase 1 / Phase 2 | 208 | GlaxoSmithKlineINDUSTRY | 13 | May 6, 2026 | clinicaltrials |
| NCT04439123 | Testing AZD5363 as a Potential Targeted Treatment in Cancers With AKT Genetic Changes (MATCH-Subprotocol Y) | active not recruiting | Phase 2 | 35 | National Cancer Institute (NCI)NIH | 1 | May 6, 2026 | clinicaltrials |
| NCT04439175 | Testing GDC-0032 (Taselisib) as a Potential Targeted Treatment in Cancers With PIK3CA Genetic Changes (MATCH-Subprotocol I) | active not recruiting | Phase 2 | 70 | National Cancer Institute (NCI)NIH | 1 | May 6, 2026 | clinicaltrials |
| NCT07084896 | Sub-study of Belantamab Mafodotin (GSK2857916) in Combination With Nirogacestat in Participants With RRMM | active not recruiting | Phase 1 / Phase 2 | 106 | GlaxoSmithKlineINDUSTRY | 13 | May 6, 2026 | clinicaltrials |
| NCT07448935 | One Gene, Two Diseases: the Pathologic Role of IGLV1-44 in AL Amyloidosis and POEMS(ALPS) | recruiting | — | 100 | Fondazione IRCCS Policlinico San Matteo di PaviaOTHER | 1 | May 6, 2026 | clinicaltrials |
| NCT07567014 | Emapalumab Prophylaxis of Bispecific T-Cell Engagers (BiTEs) Associated CRS and ICANS | not yet recruiting | Phase 2 | 60 | NYU Langone HealthOTHER | 1 | May 6, 2026 | clinicaltrials |
| NCT01177527 | Questionnaire and Tissue Banking For Multiple Myeloma, Waldenstrom Macroglobulinemia and Related Disorders | active not recruiting | — | 656 | Dana-Farber Cancer InstituteOTHER | 1 | May 5, 2026 | clinicaltrials |
| NCT04771572 | Study of Oral Administration of LP-118 in Patients With Relapsed or Refractory CLL, SLL, MDS, MDS/MPN, AML, CMML-2, MPN-BP, ALL, MF, NHL, RT, MM or T-PLL. | recruiting | Phase 1 | 100 | Newave Pharmaceutical IncINDUSTRY | 1 | May 5, 2026 | clinicaltrials |
| NCT04888741 | Methods of T Cell Depletion Trial (MoTD)(MoTD) | recruiting | Phase 2 | 400 | University of BirminghamOTHER | 1 | May 5, 2026 | clinicaltrials |
| NCT05490771 | Testing Copanlisib as a Potential Targeted Treatment in Cancers With PIK3CA Mutations (MATCH-Subprotocol Z1F) | active not recruiting | Phase 2 | 35 | National Cancer Institute (NCI)NIH | 1 | May 5, 2026 | clinicaltrials |
| NCT07226609 | A Dietary Study for People With Multiple Myeloma | recruiting | N/A | 220 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | May 5, 2026 | clinicaltrials |
| NCT03319667 | A Study to Investigate the Clinical Benefit of Isatuximab in Combination With Bortezomib, Lenalidomide and Dexamethasone in Adults With Newly Diagnosed Multiple Myeloma Not Eligible for Transplant(IMROZ) | active not recruiting | Phase 3 | 475 | SanofiINDUSTRY | 21 | May 4, 2026 | clinicaltrials |
| NCT07564219 | BEAM-MM - β-Hydroxybutyrate-Enhanced Adaptive Immunity in Multiple Myeloma(BEAM-MM) | recruiting | N/A | 45 | Universitätsklinikum Hamburg-EppendorfOTHER | 1 | May 4, 2026 | clinicaltrials |
| NCT07446777 | FAST-M: Prolonged Overnight Fasting and Mediterranean Dietary Intervention for Patients With Multiple Myeloma or Its Precursor Disease(FAST-M) | recruiting | N/A | 120 | University of MiamiOTHER | 1 | May 1, 2026 | clinicaltrials |
| NCT04653246 | Isatuximab, Lenalidomide, Bortezomib, and Dexamethasone in NDMM | active not recruiting | Phase 2 | 52 | Jacob Laubach, MDOTHER | 1 | Apr 30, 2026 | clinicaltrials |
| NCT05014646 | Leflunomide for the Treatment of High-Risk Smoldering Multiple Myeloma in African-American and European-American Patients | active not recruiting | Phase 2 | 27 | City of Hope Medical CenterOTHER | 1 | Apr 30, 2026 | clinicaltrials |
| NCT05889221 | Multicenter Phase 2 Study of Subcutaneous Isatuximab Plus Bortezomib, Lenalidomide and Dexamethasone in the Treatment of Newly Diagnosed Transplant Ineligible Multiple Myeloma | active not recruiting | N/A | 74 | Poitiers University HospitalOTHER | 1 | Apr 30, 2026 | clinicaltrials |
| NCT04888039 | Follow-up of Patients With Multiple Myeloma in the West-Occitanie Region "Living With a Myeloma in West-Occitanie"(VAMOS) | recruiting | — | 2,000 | University Hospital, ToulouseOTHER | 1 | Apr 29, 2026 | clinicaltrials |
| NCT02911571 | PRospective Multiple Myeloma Impact Study(PROMMIS) | active not recruiting | N/A | 250 | SkylineDxINDUSTRY | 1 | Apr 28, 2026 | clinicaltrials |
| NCT03141437 | Decision Aid Website in Helping to Make Decisions About Fertility in Participants With Cancer | active not recruiting | N/A | 130 | M.D. Anderson Cancer CenterOTHER | 1 | Apr 24, 2026 | clinicaltrials |
| NCT04960579 | P-BCMA-ALLO1 Allogeneic CAR-T Cells in the Treatment of Subjects With Multiple Myeloma(MM) | active not recruiting | Phase 1 | 275 | Poseida Therapeutics, Inc.INDUSTRY | 1 | Apr 24, 2026 | clinicaltrials |
| NCT06679829 | A Study of Melphalan With or Without Siltuximab in People With Multiple Myeloma Having an Autologous Stem Cell Transplant | recruiting | Phase 2 | 215 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Apr 24, 2026 | clinicaltrials |
| NCT06988020 | "Pseudo-scanner" MRI Sequences for the Detection of Bone Lesions in Multiple Myeloma(MM-ZTE-II) | recruiting | N/A | 45 | Cliniques universitaires Saint-Luc- Université Catholique de LouvainOTHER | 1 | Apr 24, 2026 | clinicaltrials |
| NCT03633955 | Pilot Imaging Study of Leukemia(REALIZE) | recruiting | Phase 1 | 60 | University of OklahomaOTHER | 1 | Apr 23, 2026 | clinicaltrials |
| NCT04246047 | Evaluation of Efficacy and Safety of Belantamab Mafodotin, Bortezomib and Dexamethasone Versus Daratumumab, Bortezomib and Dexamethasone in Participants With Relapsed/Refractory Multiple Myeloma(DREAMM 7) | active not recruiting | Phase 3 | 494 | GlaxoSmithKlineINDUSTRY | 13 | Apr 23, 2026 | clinicaltrials |
| NCT06868654 | China Subpopulation: Evaluation of Efficacy and Safety of Belantamab Mafodotin, Bortezomib and Dexamethasone Versus Daratumumab, Bortezomib and Dexamethasone in Participants With Relapsed/Refractory Multiple Myeloma(DREAMM 7) | active not recruiting | Phase 3 | 72 | GlaxoSmithKlineINDUSTRY | 1 | Apr 23, 2026 | clinicaltrials |
| NCT06868667 | Japan Expansion Cohort: Evaluation of Efficacy and Safety of Belantamab Mafodotin, Bortezomib and Dexamethasone Versus Daratumumab, Bortezomib and Dexamethasone in Participants With Relapsed/Refractory Multiple Myeloma(DREAMM 7) | active not recruiting | Phase 3 | 24 | GlaxoSmithKlineINDUSTRY | 1 | Apr 23, 2026 | clinicaltrials |
| NCT07214324 | Integrative Multi-omics Analysis to Predict Monoclonal Gammopathies Clinical Evolution(PNRR-2022-1237) | recruiting | — | 60 | Azienda USL Reggio Emilia - IRCCSOTHER_GOV | 1 | Apr 23, 2026 | clinicaltrials |
| NCT07547007 | Benefits of a 6-month, Individualized, Hybrid, "Real-life" Adapted Physical Activity Program on the Quality of Life of Patients Treated for Multiple Myeloma(BAPAMM) | recruiting | N/A | 86 | Centre Hospitalier Metropole SavoieOTHER | 1 | Apr 23, 2026 | clinicaltrials |
| NCT03823534 | Post-Op Pain Control for Prophylactic Intramedullary Nailing. | recruiting | Phase 3 | 60 | St. Louis UniversityOTHER | 1 | Apr 22, 2026 | clinicaltrials |
| NCT05972135 | Outpatient Administration of Teclistamab or Talquetamab for Multiple Myeloma | recruiting | Phase 2 | 100 | SCRI Development Innovations, LLCOTHER | 1 | Apr 22, 2026 | clinicaltrials |
| NCT02726750 | Observational Prospective Research Study In Monoclonal Gammopathies leadINg to Myeloma | recruiting | — | 200 | M.D. Anderson Cancer CenterOTHER | 1 | Apr 21, 2026 | clinicaltrials |
| NCT05392946 | Iberdomide, Daratumumab, Bortezomib, and Dexamethasone for Treatment of Newly Diagnosed Multiple Myeloma, IDEAL Study | active not recruiting | Phase 1 / Phase 2 | 49 | Mayo ClinicOTHER | 1 | Apr 21, 2026 | clinicaltrials |
| NCT05646576 | Defining the Role of Palliative carE for Patients With Hematologic Malignancies Undergoing Adoptive CEllular Therapy(PEACE) | recruiting | N/A | 90 | Massachusetts General HospitalOTHER | 1 | Apr 21, 2026 | clinicaltrials |
| NCT07542418 | Study of Thiotepa Combination With Melphalan (TM Protocol) Conditioning for Autologous Hematopoietic Stem Cell Transplantation in Multiple Myeloma:A Prospective Randomized Controlled Clinical Trial | not yet recruiting | N/A | 204 | First Affiliated Hospital Xi'an Jiaotong UniversityOTHER | 0 | Apr 21, 2026 | clinicaltrials |
| NCT03761108 | Phase 1/2 Study of Linvoseltamab in Adult Patients With Relapsed or Refractory Multiple Myeloma(LINKER-MM1) | recruiting | Phase 1 / Phase 2 | 387 | Regeneron PharmaceuticalsINDUSTRY | 7 | Apr 20, 2026 | clinicaltrials |
| NCT04166565 | Daratumumab Combined With Bortezomib, Cyclophosphamide and Dexamethasone for the Treatment of Multiple Myeloma Patients Presenting With Extramedullary Disease(EMN19) | active not recruiting | Phase 2 | 41 | Stichting European Myeloma NetworkNETWORK | 3 | Apr 20, 2026 | clinicaltrials |
| NCT04561492 | Relevance of [68Ga]Ga -PentixaFor-PET for Initial Staging and Therapeutic Evaluation of Multiple Myeloma(PentiMyelo) | active not recruiting | Phase 2 | 45 | Nantes University HospitalOTHER | 1 | Apr 20, 2026 | clinicaltrials |
| NCT05909059 | CAR T-cell Therapy in Patients With Renal Dysfunction | recruiting | Phase 2 | 20 | Northside Hospital, Inc.OTHER | 1 | Apr 20, 2026 | clinicaltrials |
| NCT05969860 | At-Home Cancer Directed Therapy Versus in Clinic for the Treatment of Patients With Advanced Cancer | recruiting | Phase 2 | 220 | Mayo ClinicOTHER | 1 | Apr 20, 2026 | clinicaltrials |
Data updated 23 days agoSource updated May 8, 2026source: clinicaltrials